2025
SJR Q1
JCR Q1 · 7
OA
SCIE
Journal detail
npj Regenerative Medicine
- Publisher
- Nature Research
- Country
- United Kingdom · Western Europe
- Type
- journal
- ISSN
-
20573995
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,92
- Quartile Q1
- H-Index 52
- Cites/doc 6,44
- Docs (3y) 184
- Cites (3y) 1.286
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 7
- 5Y JIF 8,1
- JCI 1,37
WoS indexes
- SCIE
Subject classification
Categories (SJR)
- Biomedical Engineering Q1
- Cell Biology Q1
- Developmental Biology Q1
- Medicine (miscellaneous) Q1
Areas
- Biochemistry, Genetics and Molecular Biology
- Engineering
- Medicine
WoS categories
- Cell & Tissue Engineering | Engineering, Biomedical
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,92 | 7 | 8,1 | 1,37 | Q1 | 52 |
| 2024 | Q1 | Q1 | 2,058 | 6,5 | 8,5 | 1,42 | Q1 | 44 |
| 2023 | Q1 | Q1 | 1,575 | 6,4 | 7,9 | 1,28 | Q1 | 44 |
| 2022 | Q1 | Q1 | 1,967 | 7,2 | 9,2 | 1,53 | Q1 | 44 |
| 2021 | Q1 | Q1 | 2,413 | 14,4 | 13,5 | 1,68 | Q1 | 44 |
| 2020 | Q1 | Q1 | 2,491 | 10,4 | 11,5 | 1,6 | Q1 | 44 |
| 2019 | Q1 | Q1 | 1,682 | 7 | 8,3 | 1,25 | Q1 | 44 |
| 2017 | — | — | — | — | — | — | — | 44 |
| 2016 | — | — | — | — | — | — | — | 44 |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | CELL & TISSUE ENGINEERING | SCIE | Q1 | Q1 | 5/32 |
| 2025 | ENGINEERING, BIOMEDICAL | SCIE | Q1 | Q1 | 21/130 |
| 2024 | CELL & TISSUE ENGINEERING | SCIE | Q1 | Q1 | 5/32 |
| 2024 | ENGINEERING, BIOMEDICAL | SCIE | Q1 | Q1 | 21/124 |
| 2023 | CELL & TISSUE ENGINEERING | SCIE | Q1 | Q1 | 5/31 |
| 2023 | ENGINEERING, BIOMEDICAL | SCIE | Q1 | Q1 | 19/123 |
| 2022 | CELL & TISSUE ENGINEERING | SCIE | Q1 | Q1 | 5/29 |
| 2022 | ENGINEERING, BIOMEDICAL | SCIE | Q1 | Q1 | 19/96 |
| 2021 | CELL & TISSUE ENGINEERING | SCIE | Q1 | Q1 | 2/29 |
| 2021 | ENGINEERING, BIOMEDICAL | SCIE | Q1 | Q1 | 5/98 |
| 2020 | CELL & TISSUE ENGINEERING | SCIE | Q1 | Q1 | 3/29 |
| 2020 | ENGINEERING, BIOMEDICAL | SCIE | Q1 | Q1 | 5/89 |
| 2019 | CELL & TISSUE ENGINEERING | SCIE | Q1 | Q1 | 3/29 |
| 2019 | ENGINEERING, BIOMEDICAL | SCIE | Q1 | Q1 | 9/87 |